Benzinga | Sep 29, 2021 09:22AM EDT

Maxim Group Initiates Coverage On Clarus Therapeutics Hldgs with Buy Rating, Announces Price Target of $13

Maxim Group analyst Naz Rahman initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Buy rating and announces Price Target of $13.